TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03522649

Intervention type: DRUG
Group type: OTHER
Intervention: Napabucasin
Description: Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8\~12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Napabucasin
Description: Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8\~12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
Study: NCT00989443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir gel
Description: topical gel applied once a week for 3 weeks
Study: NCT02985775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor-derived CMVpp65-specific T cells
Description: About 1 million per kg CMVpp65-specific T cells will be infused once acute GVHD ocurred post haploidentical transplantation.
Study: NCT03956082

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultravision™ Visual Field Clearing System
Description: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultravision Ionwand™
Description: The Ionwand™ is introduced into the abdomen through either the Ultravision™ 5mm Trocar or a 2.5 mm percutaneous catheter. The Ionwand™ provides the source of electrons that create the negative ions that transiently charge the surgical smoke particles and accelerate their sedimentation.
Study: NCT03404921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESTD
Description: During the ESTD procedure,after marking and submucosal injection, incisions were made at both the anal and oral sides of the lesion, and the submucosa under the lesion was then dissected to create a tunnel between the distal and proximal incisions. When the endscope reached the lower incision, the distal end of the esophageal lumen could be visualized , then two lateral mucosal incisions were made, thus completing the ESD procedure.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ESD
Description: The ESD procedure involved marking,injection,circumferential cutting, submucosal dissection.
Study: NCT00467597

Intervention type: DRUG
Intervention: Levodopa (delivered intravenously)
Description: IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit.
Study: NCT03526484

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The provider will review the urinalysis results prior to conducting the in-office procedure and will make clinical decisions taking into account those results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The provider will not review the urinalysis results prior to conducting the in-office procedure, and therefore will not make clinical decisions taking those results into account.
Study: NCT02721563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Glycididazole
Description: Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
Study: NCT03562182

Intervention type: OTHER
Intervention: blood draw
Description: Blood draw (2.5mL) to assess mRNA LPCAT1 levels
Study: NCT03690323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.
Study: NCT00404703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: As prescribed
Study: NCT01962922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCP-Tacro
Description: once-daily extended release tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus -IR
Description: twice daily capsules
Study: NCT03932968

Intervention type: PROCEDURE
Intervention: pH-metry during 24 hours
Description: For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry will be performed
Study: NCT04128332

Intervention type: RADIATION
Group type: OTHER
Intervention: Pre-operative stereotactic ablative body radiotherapy
Description: Stereotactic ablative body radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding tissues.
Study: NCT04661969

Intervention type: PROCEDURE
Intervention: Surgery
Description: (group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).

Intervention type: PROCEDURE
Intervention: Surgery
Description: (group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).

Intervention type: PROCEDURE
Intervention: Surgery
Description: (group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).

Intervention type: PROCEDURE
Intervention: Surgery
Description: (group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).
Study: NCT01477203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 2-4 weeks, 5-10mg, max 20mg
Study: NCT03777735

Intervention type: PROCEDURE
Intervention: human bone graft screw
Description: All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.
Study: NCT00568685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine Hydrochloride
Description: Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine hydrochloride
Description: Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine hydrochloride
Description: Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.~Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days
Study: NCT01418027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Description: Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise
Description: Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
Study: NCT01104870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C
Description: oral
Study: NCT01433965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
Study: NCT02317042

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juno
Description: Juno device set to ST mode with participant's current therapy settings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juno
Description: Juno device set to AutoEPAP iVAPS mode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juno
Description: Juno device set to Fixed EPAP iVAPS mode.
Study: NCT04495998

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Brief Motor Scale_portuguese version (BMS_pt)
Description: translate, adapt and validate Brief Motor Scale for portuguese population with schizophrenia
Study: NCT04604366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: it stimulates uterine contractions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: it stimulates uterine contractions
Study: NCT04318964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAEST16001 cells
Description: The patients in the dose increasing part and the expanding part received the intravenous reinfusion of TAEST16001 cells on the 5th day (i.e. the interval was 4 days) after the lymphocyte elimination chemotherapy: If the dose level of reinfusion was 1 and 2, the planned total amount of TAEST16001cells (calculated by TCR-T positive cells) was given a single reinfusion on the 1st day of the study. If the dose level of reinfusion was 3 and 4,then the total amount of TAEST16001cells (calculated by TCR-T positive cells) was planned to be reinjected in 60% and 40% proportion on the first and second day of the study.~After the first reinfusion of TAEST16001 cells, the patients will be given a small dose of IL-2 subcutaneously (study day 1 to day 14), 500000 U / time. The first injection will be carried out within 30 minutes after the cell reinfusion, twice a day (interval 10-12 hours), for 14 days.
Study: NCT03374111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colla corii asini
Description: 15 g Colla corii asini granule daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a Simulate Agent of Colla corii asini granule
Description: 15 g a Simulate Agent of Colla corii asini granule daily for 8 weeks
Study: NCT03660605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation
Description: Participants will complete 6 weeks of walking training (3x/week). During each session, participants will walk on a treadmill for up to 20 minutes (stepping to a metronome at 85% of typical cadence) followed by overground walking for up to 15 minutes (stepping to a metronome at 115% of typical cadence).
Study: NCT04537351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYP-001
Description: The active agent in CYP-001 is Cymerus mesenchymal stem cells (MSCs), which are derived through a proprietary induced pluripotent stem cell (iPSC) and mesenchymoangioblast (MCA)-derived production process.
Study: NCT02790762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.
Study: NCT02470624

Intervention type: OTHER
Intervention: treatment following current guideline
Study: NCT01013480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen
Description: A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
Study: NCT01062399

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
Study: NCT04592328

Intervention type: OTHER
Intervention: Bacterial cultures taken during surgery.
Description: Cultures taken from skin, subcutaneous tissue, surigal materials and surgical gloves at incision and after two hours.
Study: NCT01062399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent RAD001 2.5 mg/day
Description: During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent RAD001 5 mg/day
Description: During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation RAD001 10 mg/day
Description: Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
Study: NCT04032457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase A - olifilcon B with Tangible Coatings
Description: Daily disposable silicone hydrogel contact lens
Study: NCT01358305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Blend
Description: Single intake of approximately 20 grams of total protein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein Blend
Description: Single intake of approximately 20 grams of total protein
Study: NCT04026958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
Study: NCT04026958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
Study: NCT03477591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-based information
Description: Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-based information
Description: Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: Patient Decision Aid for prostate cancer screening decision

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham information
Description: Educational information not specific to PSA testing or cancer screening
Study: NCT03307824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic glue IfabondTM
Description: Use of the synthetic glue IfabondTM

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glue-Free Suture Technique
Description: Suture Technique
Study: NCT04465305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: entraped treatment
Description: patients with tarlov cysts treated by entraped and plasty nerve root

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasty treatment
Description: patients with tarlov cysts treated by plasty nerve root

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plasty treatment
Description: patients with tarlov cysts treated by plasty nerve root
Study: NCT02369939

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation
Description: Radiotherapy 55,8 Gy - 59,4 Gy
Study: NCT04032457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase A - olifilcon B with Tangible Coatings
Description: Daily disposable silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase A - olifilcon B with Tangible Coatings
Description: Daily disposable silicone hydrogel contact lens
Study: NCT02369939

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Irradiation
Description: Radiotherapy 55,8 Gy - 59,4 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: MMC w1, w5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: MMC w1, w5
Study: NCT01062399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation RAD001 10 mg/day
Description: Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation RAD001 10 mg/day
Description: Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
Study: NCT01062399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: post-radiation RAD001 10 mg/day
Description: Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation RAD001 10 mg/day
Description: Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation temozolomide
Description: Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation temozolomide
Description: Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation temozolomide
Description: Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: post-radiation temozolomide
Description: Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation temozolomide
Description: Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)
Study: NCT02778048

Intervention type: OTHER
Intervention: MRI (magnetic resonance imaging)
Description: Assessment of the sphincter

Intervention type: OTHER
Intervention: US (ultra sound)
Description: Assessment of the sphincter

Intervention type: OTHER
Intervention: FLIP (functional lumen imaging probe)
Description: Assessment of the sphincter
Study: NCT04032457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase B - etafilcon A with Tangible Coatings
Description: Daily disposable hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase B - etafilcon A with Tangible Coatings
Description: Daily disposable hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase B - etafilcon A with Tangible Coatings
Description: Daily disposable hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase B - etafilcon A with Tangible Coatings
Description: Daily disposable hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase B - etafilcon A with Tangible Coatings
Description: Daily disposable hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase B - etafilcon A with Tangible Coatings
Description: Daily disposable hydrogel contact lens
Study: NCT02328456

Intervention type: OTHER
Group type: OTHER
Intervention: SMS and free eye drops
Description: The SMS reminder message will sent to the SMS associated with free eye drops group patients 1 week and 1 day before there appointment to remind them the exact time and address of the revisit appointment.The eye drops will be offered free to the the SMS associated with free eye drops group patients when they revisit on time.
Study: NCT03138512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days
Study: NCT02778048

Intervention type: OTHER
Intervention: HRAM (high resolution anal manometry)
Description: Assessment of the sphincter